Methods for determining prognoses and therapeutic interventions for ovarian carcinomas
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsHeide Ford, Kian Behbakht, Andrew Thorburn
Life of this patent
Estimating the term…
Abstract
Methods for determining the prognosis and therapeutic interventions for cancer and for utilizing the expression of the homeoprotein Six1 to determine the prognosis and therapeutic interventions for cancer, in particular for ovarian carcinomas.
Claims11
A method for determining therapeutic intervention in a subject having ovarian cancer comprising the steps of:
- obtaining a biological sample from the subject;
- determining whether the biological sample possesses an overexpression of at least one of Six1 protein or Six1 RNA;
- and
- selecting a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agent for therapy when at least one of Six1 protein or Six1 RNA is not overexpressed.
A method for determining therapeutic intervention for a subject having ovarian carcinoma comprising the steps of:
- obtaining an ovarian tumor sample from the subject;
- determining an amount of Six1 protein or Six1 mRNA expressed in the ovarian tumor sample;
- determining whether the amount of Six1 protein or Six1 mRNA is over-expressed in the ovarian minor sample compared to a control;
- and
- selecting a TRAIL agent for therapy when Six1 is not overexpressed.
A method for determining the prognosis of a subject with ovarian carcinoma comprising the steps of:
- obtaining an ovarian tumor sample from the subject;
- determining the amount of Six t protein or Six1 RNA expressed in the tumor sample;
- and
- forming a prognosis based on the amount of Six1 protein or Six 1 RNA.
A method for determining therapeutic intervention in a subject having ovarian cancer comprising the steps of:
- obtaining a biological sample from the subject;
- determining whether the biological sample possesses an overexpression of a Six1 protein or Six1 RNA;
- and
- selecting a non-tumor necrosis factor-related apoptosis-inducing ligand agent for therapy that is not cross-resistant to chemotherapy when the biological sample does possess the over-expression.
A method for determining therapeutic intervention in a subject having ovarian carcinoma comprising the steps of:
- obtaining an ovarian tumor sample from the subject;
- determining whether an amount of Six1 protein or Six] mRNA is over-expressed in the ovarian minor sample;
- and
- selecting a therapy that does not include tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) when Six1 protein or Six1 mRNA is over-expressed.
Dependencies are inferred from the claim text.